Table 2. Association of BRAF and KRAS mutational status with clinicopathological features in colorectal cancer.
| KRAS/BRAF status | Wild/wild |
KRAS mutant
|
BRAF mutant | ||||
|---|---|---|---|---|---|---|---|
| Clinicopathological features | n=135 | G12X n=53 | G13X n=26 | Total (G12X+G13X) n=79 | V600E n=15 | *P-value | Overall n=229 |
| Age at diagnosis (median) | 62 (27–83) | 62 (40–85) | 68 (41–79) | 63 (40–85) | 62 (30–80) | ||
| Gender | |||||||
| Female | 47 (34.8%) | 27 (50.9%) | 13 (50.0%) | 40 (50.6%) | 8 (53.3%) | 0.1082 | 95 |
| Male | 88 (65.2%) | 26 (49.1%) | 13 (50.0%) | 39 (49.4%) | 7 (46.7%) | 134 | |
| ECOG PS | |||||||
| 0–1 | 115 (85.2%) | 46 (86.8%) | 22 (84.6%) | 68 (86.1%) | 13 (86.7%) | 0.7898 | 196 |
| >2 | 9 (6.7%) | 4 (7.5%) | 3 (11.5%) | 7 (8.9%) | 2 (13.3%) | 18 | |
| Unknown | 11 (8.1%) | 3 (5.7%) | 1 (3.8%) | 4 (5.1%) | 0 (0.0%) | 15 | |
| Tumour location | |||||||
| Right sided | 28 (20.7%) | 14 (26.4%) | 12 (46.2%) | 26 (32.9%) | 9 (60.0%) | 0.0391 | 63 |
| Left sided | 41 (30.4%) | 13 (24.5%) | 3 (11.5%) | 16 (20.3%) | 3 (20.0%) | 60 | |
| Rectum | 64 (47.4%) | 25 (47.2%) | 11 (42.3%) | 36 (45.6%) | 3 (20.0%) | 103 | |
| Other | 2 (1.5%) | 1 (1.9%) | 0 (0.0%) | 1 (1.3%) | 0 (0.0%) | 3 | |
| Disease status | |||||||
| Advanced | 82 (60.7%) | 26 (49.1%) | 11 (42.3%) | 37 (46.8%) | 9 (60.0%) | 0.2269 | 128 |
| Recurrence | 53 (39.3%) | 27 (50.9 %) | 15 (57.7%) | 42 (53.2%) | 6 (40.0%) | 101 | |
| Histological subtype | |||||||
| Well | 28 (20.7%) | 8 (15.1%) | 7 (26.9%) | 15 (19.0%) | 1 (6.7%) | <0.0001 | 44 |
| Mod | 91 (67.4%) | 37 (69.8%) | 18 (69.2%) | 55 (69.6%) | 5 (33.3%) | 151 | |
| por/sig/muc | 10 (7.4%) | 5 (9.4%) | 1 (3.8%) | 6 (7.6%) | 9 (60.0%) | 25 | |
| Other | 1 (0.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0%) | 0 (0.0%) | 1 | |
| Unknown | 5 (3.7%) | 3 (5.7%) | 0 (0.0%) | 3 (3.8%) | 0 (0.0%) | 8 | |
| Metastatic sites | |||||||
| Liver | 90 (66.7%) | 31 (58.5%) | 15 (57.7 %) | 46 (58.2%) | 10 (66.7%) | 0.6595 | 146 |
| Peritoneum | 30 (22.2%) | 11 (20.8%) | 4 (15.4%) | 15 (20.0%) | 9 (60.0%) | 0.0062 | 54 |
| Lung | 42 (31.1%) | 21 (39.6%) | 10 (38.5%) | 31 (39.2%) | 5 (33.3%) | 0.6867 | 78 |
| CNS | 1 (0.7%) | 0 (0.0%) | 1 (3.8%) | 1 (1.3%) | 0 (0.0%) | 0.3503 | 2 |
| Bone | 9 (6.7%) | 3 (5.7%) | 2 (7.7%) | 5 (6.3%) | 2 (13.3%) | 0.7736 | 16 |
| Number of metastatic sites | |||||||
| >2 | 64 (47.4%) | 23 (43.4%) | 14 (53.8%) | 37 (46.8%) | 10 (66.7%) | 0.4078 | 111 |
| <1 | 71 (52.6%) | 30 (56.6%) | 12 (46.2%) | 42 (53.2%) | 5 (33.3%) | 118 | |
| WBC | |||||||
| WBC>10000 | 9 (6.7%) | 4 (7.5%) | 2 (7.7%) | 6 (7.6%) | 0 (0.0%) | 0.7622 | 15 |
| WNL | 100 (74.1%) | 38 (71.7%) | 20 (76.9%) | 58 (73.4%) | 14 (93.3%) | 172 | |
| Unknown | 26 (19.3%) | 11 (20.8%) | 4 (15.4%) | 15 (20.2%) | 1 (6.7%) | 42 | |
| ALP | |||||||
| ALP>300 | 59 (43.7%) | 18 (34.0%) | 12 (46.2%) | 30 (38.0%) | 6 (40.0%) | 0.6635 | 95 |
| WNL | 49 (36.3%) | 24 (45.3%) | 10 (38.5%) | 34 (43.0%) | 8 (53.3%) | 91 | |
| Unknown | 27 (20.0%) | 11 (20.8%) | 4 (15.4%) | 15 (20.0%) | 1 (6.7%) | 43 | |
| First-line regimen | |||||||
| IRI-based | 24 (17.8%) | 6 (11.3%) | 2 (7.7%) | 8 (10.1%) | 1 (6.7%) | 0.4062 | 33 |
| OXA-based | 85 (63.0%) | 37 (69.8%) | 17 (65.4%) | 54 (68.4%) | 13 (86.7%) | 152 | |
| Others | 26 (19.3%) | 10 (18.9%) | 7 (26.9%) | 17 (21.5%) | 1 (6.7%) | 44 | |
| Anti-EGFR treatment | |||||||
| Yes | 86 (63.7%) | 1 (1.9%) | 1 (3.8%) | 2 (2.5%) | 5 (33.3%) | <0.0001 | 93 |
| No | 44 (32.6%) | 52 (98.1%) | 25 (96.2%) | 77 (97.5%) | 10 (66.7%) | 131 | |
| Unknown | 5 (3.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 5 | |
Abbreviations: CNS=central nervous system; ECOG=Eastern Cooperative Oncology Group; EGFR=epidermal growth factor receptor; PS=performance status; well=well-differentiated adenocarcinoma; mod=moderately differentiated adenocarcinoma; por=poorly differentiated adenocarcinoma; muc=mucinous carcinoma; sig=signet-ring cell carcinoma; CNS=central nervous system; IRI=irinotecan; OXA=oxaliplatin, ALP=alkaline phosphatase; WNL=within normal range; WBC=white blood cells.
Patients with both wild-type KRAS and wild-type BRAF were designated as wild/wild. All patients with KRAS mutations (n=79) either in codon 12 (G12X) or in codon 13 (G13X) are shown as total (G12X+G13X).
*P-values calculated between wild-type KRAS and BRAF (wild/wild), KRAS12 mutant (G12X), KRAS13 mutant (G13X), and BRAF mutant (V600E) groups.